Spire Healthcare Group (LON:SPI) PT Raised to GBX 300

Spire Healthcare Group (LON:SPI) had its price objective increased by Berenberg Bank from GBX 286 ($3.56) to GBX 300 ($3.73) in a report issued on Wednesday morning, Digital Look reports. They currently have a buy rating on the stock.

Separately, JPMorgan Chase & Co. restated an overweight rating and set a GBX 295 ($3.67) target price on shares of Spire Healthcare Group in a research report on Monday, February 26th.

Spire Healthcare Group Stock Up 3.3 %

Shares of LON SPI opened at GBX 246.40 ($3.07) on Wednesday. The firm’s 50-day moving average price is GBX 237.41 and its 200-day moving average price is GBX 228.84. The company has a current ratio of 0.69, a quick ratio of 0.74 and a debt-to-equity ratio of 170.37. The stock has a market capitalization of £995.79 million, a price-to-earnings ratio of 3,521.43, a P/E/G ratio of 1.06 and a beta of 0.99. Spire Healthcare Group has a 12-month low of GBX 204 ($2.54) and a 12-month high of GBX 321.71 ($4.00).

Spire Healthcare Group Increases Dividend

The firm also recently announced a dividend, which will be paid on Friday, June 21st. Stockholders of record on Thursday, May 23rd will be given a dividend of GBX 2.10 ($0.03) per share. This represents a dividend yield of 0.89%. This is a boost from Spire Healthcare Group’s previous dividend of $0.50. The ex-dividend date of this dividend is Thursday, May 23rd. Spire Healthcare Group’s dividend payout ratio is currently 4,285.71%.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.